Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.


AIM To identify suitable biomarkers of response to bevacizumab (BV) - it remains an open question. The measurement of serum vascular endothelial growth factor (VEGF) has been proposed as a predictive factor for this drug, even if literature data are contradictory. METHODS We prospectively evaluated the role of BV, total and not BV-bound VEGF and… (More)
DOI: 10.3748/wjg.v22.i27.6287


  • Presentations referencing similar topics